Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Date:10/26/2009

2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Zerenex (ferric citrate), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for Zerenex; our ability to meet anticipated development timelines for Zerenex due to recruitment, clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our planned Phase 3 clinical program the efficacy and safety of Zerenex observed in the previous Phase 2 and the Open Label Extension clinical trials, and the effects on IV iron and EPO use observed in these previous clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that oc
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
11. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Lumin Medical ... the assets of PatientTrak, the leading provider of on-demand ... from Illinois to ... is Lumin which means light and our mission is ... patient satisfaction, increase efficiencies and reduce costs," said ...
(Date:7/14/2014)... N.J. , July 14, 2014  Invivotek ... LLC is pleased to announce that its animal ... Association for the Assessment and Accreditation of Laboratory ... treatment of animals in science worldwide through voluntary ... standards for animal care and use in 38 ...
(Date:7/14/2014)... 14, 2014  Remedy Informatics, the leading provider ... and life sciences research, announced that it has ... to build the first-ever national patient registry devoted ... pancreatitis. "The National Pancreas Foundation is ... thoughtful and committed organizations can effect upon society ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
... 4, 2012  Elevation Pharmaceuticals, Inc. announced today the closing ... investor Novo Ventures , to fund development of Elevation,s ... disease (COPD). All previous investors participated in the round, including ... Capital and Mesa Verde Venture Partners . In ...
... 4, 2012 /PRNewswire-iReach/ -- DFH Pharma, ... focused exclusively in the HIV-1 therapeutic space, announced ... medicinal chemistry services to support DFH efforts to ... drugs. Maturation inhibitors are a novel class of ...
Cached Medicine Technology:Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 2Elevation Pharmaceuticals Completes $30 Million Series B Financing to Advance Aerosol COPD Therapy 3DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:7/14/2014)... This report provides quantitative analysis ... The analysis includes market size data by revenue ... company share data by revenue in 2013 for ... It uses data and information sourced from proprietary ... , Scope,     Information on market ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 BCC ... report, SYNTHETIC BIOLOGY: GLOBAL MARKETS , the ... to nearly $11.9 billion in 2018, with a ... Enabled products account for the fastest growing segment, ... CAGR. Synthetic biology-enabled products in the pharmaceutical/diagnostics, chemical, ...
(Date:7/14/2014)... July 14, 2014 Secure Decisions, a ... is partnering with the Software Assurance Marketplace (SWAMP) to ... the software that drives everyday life. , The SWAMP, ... housed in the Morgridge Institute for Research, is funded ... advance software security practices by building a free facility ...
(Date:7/14/2014)... Clearwater, Florida (PRWEB) July 14, 2014 ... Summer Open House event will be held at the ... Wednesday July 16th from 4-8pm. Wine and other refreshments ... advantage of retail discounts on beauty products ... skin treatment known as dermaplaning. , Dermaplaning (also ...
(Date:7/14/2014)... July 14, 2014 The Encino ... now offering Lumineers and porcelain veneers. These ... that require more preparation and greater loss of healthy ... shells to conceal visible flaws on the tooth. Encino ... closely with patients to ensure they offer the most ...
Breaking Medicine News(10 mins):Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 2Health News:Global Market for Synthetic Biology to Reach Nearly $11.9 Billion by 2018 — Enabled Products Account for the Fastest Growing Segment with 36.7% CAGR 3Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2
... finds cavities before X-rays allowing, dentists to ... TORONTO, July 3 /PRNewswire/ - Quantum Dental ... technology which,detects and monitors the early onset of ... reduces the number of invasive and painful procedures,and ...
... G8 failure on food prices, biofuels, and climate ... world,s population - at risk of hunger, warns,anti-poverty ... ahead of the G8,summit in Hokkaido, Japan, ActionAid ... has Contributed to the Global Food Crisis and ...
... completely fabricated,item about GO3 Omega-3 fish oil capsules ... Star magazine, none of the parties named in ... magazine prior to publication., (Photo: http://www.newscom.com/cgi-bin/prnh/20080702/LAW528 ... and will vigorously pursue any,organization making false claims ...
... Roger Mason Jr,Washington Wizards Guard and Washington, ... a Cause on July 29 featuring bowling at ... coming out to support the,cause, including Brendan Haywood ... Anthony, Allen Iverson, Vince Carter, Kevin Durant, and,Chris ...
... Technology could one day help tailor treatments to individual patients, ... new technique for finding and analyzing stray cancer cells in ... for doctors to one day not only determine the genetic ... cells and adjust treatments accordingly. , "I think this ...
... John Albright, MD, will join three other physicians as a 2008 ... , ... Orlando, Florida (PRWEB) July 2, 2008 -- ... three other physicians as a 2008 American Orthopaedic Society for ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
Round knurled handle. Overall length 130 mm....
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
Round knurled handle. Overall length 130 mm....
Hosford foreign body spud 4 3/4 inches, gouge blade 1 x 7 mm rounded tip, angled to left....
Medicine Products: